Earnings summaries and quarterly performance for Carlyle Group.
Executive leadership at Carlyle Group.
Harvey M. Schwartz
Detailed
Chief Executive Officer
CEO
Jeff Nedelman
Detailed
Co-President
Jeffrey W. Ferguson
Detailed
General Counsel
John C. Redett
Detailed
Chief Financial Officer and Head of Corporate Strategy
Justin Plouffe
Detailed
Chief Financial Officer
Lindsay P. LoBue
Detailed
Chief Operating Officer
Mark Jenkins
Detailed
Co-President
Board of directors at Carlyle Group.
Afsaneh Beschloss
Detailed
Director
Anthony Welters
Detailed
Director
David M. Rubenstein
Detailed
Co-Chairman of the Board
Derica W. Rice
Detailed
Director
James H. Hance, Jr.
Detailed
Director
Lawton W. Fitt
Detailed
Director
Linda H. Filler
Detailed
Director
Mark S. Ordan
Detailed
Lead Independent Director
Sharda Cherwoo
Detailed
Director
William E. Conway, Jr.
Detailed
Co-Chairman of the Board
William J. Shaw
Detailed
Director
Research analysts who have asked questions during Carlyle Group earnings calls.
Alexander Blostein
Goldman Sachs
5 questions for CG
Also covers: AB, AMG, AMP +31 more
Brian Bedell
Deutsche Bank
5 questions for CG
Also covers: AMG, AMTD, APO +22 more
Brian McKenna
Citizens JMP Securities
5 questions for CG
Also covers: ARCC, ARES, BX +14 more
Kenneth Worthington
JPMorgan Chase & Co.
5 questions for CG
Also covers: APO, ARES, BAM +27 more
Michael Cyprys
Morgan Stanley
5 questions for CG
Also covers: AAMI, AMP, AMTD +30 more
Patrick Davitt
Autonomous Research
5 questions for CG
Also covers: ABL, AMG, APO +10 more
William Katz
TD Cowen
5 questions for CG
Also covers: AB, AMG, AMTD +25 more
Glenn Schorr
Evercore ISI
4 questions for CG
Also covers: APO, BAC, BEN +14 more
Kyle Voigt
Keefe, Bruyette & Woods
4 questions for CG
Also covers: AMTD, APO, ARES +17 more
Benjamin Budish
Barclays PLC
3 questions for CG
Also covers: AB, APO, ARES +23 more
Daniel Fannon
Jefferies Financial Group Inc.
3 questions for CG
Also covers: AB, AMG, AMTD +27 more
Michael Brown
Wells Fargo Securities
3 questions for CG
Also covers: APO, ARES, BAM +18 more
Steven Chubak
Wolfe Research
3 questions for CG
Also covers: AMP, AMTD, APO +17 more
Ben Budish
Barclays PLC
2 questions for CG
Also covers: AB, APO, ARES +19 more
Brendan O'Brien
Wolfe Research
1 question for CG
Also covers: EVR, HLI, LAZ +4 more
Brennan Hawken
UBS Group AG
1 question for CG
Also covers: AMP, AMTD, APO +26 more
Craig Siegenthaler
Bank of America
1 question for CG
Also covers: AB, AMP, AMTD +26 more
Recent press releases and 8-K filings for CG.
Carlyle CFO Transitions to Global Head of Private Equity Amid Strong Performance and Optimistic Outlook
CG
CFO Change
Guidance Update
New Projects/Investments
- Carlyle (CG) CFO, John Redett, is transitioning to Global Head of Private Equity, marking his last event in the CFO capacity.
- The company reported a strong year with record FRE over the last 12 months and $60 billion of inflows over the last six months, with the stock being a top performer in its space.
- Management is optimistic about 2026, anticipating a healthy deal environment with attractive rates, open financing markets, and accelerating M&A, leading to a busy year for new investments and monetizations.
- Carlyle revised its 2025 fundraising guidance to $50 billion and expects meaningful management fee growth over the next couple of years due to large funds coming to market.
- The wealth channel saw doubled inflows this year, and the recently launched private equity product (CPEP) is expected to accelerate meaningfully in 2026 and 2027.
Dec 9, 2025, 4:20 PM
Carlyle Discusses Strong Performance, Strategic Growth, and Leadership Transition
CG
CFO Change
Guidance Update
Revenue Acceleration/Inflection
- John Redett is transitioning from his role as CFO and Head of Corporate Strategy to Global Head of Private Equity.
- Carlyle is experiencing a strong year, with record FRE and approximately $60 billion of inflows over the last six months. The company anticipates a very healthy deal environment in 2026, with accelerating M&A and monetization.
- The firm has significant fundraising momentum, revising its 2025 guidance to $50 billion in inflows and expects meaningful management fee growth in 2026 and 2027 due to large funds coming to market.
- Carlyle is making substantial progress in its wealth channel, doubling inflows in 2025, and sees significant growth potential in its Asset-Backed Finance business, which has grown to $10 billion.
- The company aims for an FRE margin target of 40%-50%, currently at 48% in 2025, and is committed to shrinking its share count through share repurchases, having bought back $500 million year-to-date.
Dec 9, 2025, 4:20 PM
Carlyle CFO John Redett Transitions to Global Head of Private Equity Amid Strong Performance and Growth Outlook
CG
CFO Change
Guidance Update
Share Buyback
- John Redett, current CFO and Head of Corporate Strategy at Carlyle, is transitioning to Global Head of Private Equity, marking his last event as CFO.
- Carlyle reported a strong year with record FRE over the last 12 months and approximately $60 billion in inflows over the last six months. The company is on track to achieve $50 billion in inflows for the year, having raised $45 billion year to date through Q3.
- The firm anticipates significant fundraising opportunities in the next 18 months, with major flagship products like CP9 (U.S. buyout), CCOF (opportunistic credit), Infrastructure, Secondaries, Co-investment, and CLO business entering the market.
- Monetizations reached $32 billion across the firm through Q3, representing a 30%-35% increase, with Q4 net realized performance revenues expected to be multiples of Q3.
- Carlyle's FRE margin is approximately 48%, at the upper end of its 40%-50% target, with expectations for meaningful expansion through growth and scale, projecting 10%-11% FRE growth for the year. The company has repurchased $500 million in shares year to date and is focused on reducing its share count.
Dec 9, 2025, 4:20 PM
Carlyle Group-backed Adicon to Acquire Crown Bioscience
CG
M&A
New Projects/Investments
- JSR Life Sciences has entered a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited, a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group.
- The transaction is expected to close in 2026.
- This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership, positioning it to accelerate advancements in precision medicine and drug discovery for oncology.
- Crown Bioscience's Global Biospecimens business will remain fully integrated within JSR Life Sciences.
Nov 13, 2025, 8:45 AM
Carlyle Group Reports Q3 Earnings and Record AUM
CG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- The Carlyle Group reported a significant drop in third-quarter net income to $900,000 from nearly $596 million the previous year, with distributable earnings per share of 96 cents, missing analyst estimates.
- Despite the earnings miss, the firm achieved a record $474 billion in assets under management (AUM), driven by $17 billion in quarterly inflows and 11% fee revenue growth.
- Management raised full-year financial targets, expecting 10% fee-related earnings growth and $50 billion in inflows.
- The company's fee-related earnings margins stood at 48% for the quarter and year-to-date, surpassing last year's record of 46%.
Oct 31, 2025, 6:05 PM
Carlyle Reports Strong Q3 2025 Results with Increased Guidance
CG
Earnings
Guidance Update
Share Buyback
- The Carlyle Group reported Q3 2025 Fee-Related Earnings (FRE) of $312 million, an increase of 12% year-over-year, contributing to $946 million year-to-date FRE, up 16%. The firm's Assets Under Management (AUM) reached a record $474 billion, growing 7% year-to-date.
- The company achieved $17 billion in organic inflows for Q3 2025, with nearly $60 billion over the past 12 months, driven by strong contributions from credit, secondaries, and global wealth. This performance led to an updated full-year outlook for FRE growth of approximately 10% (up from 6%) and full-year inflows of $50 billion (up from $40 billion).
- Key business segments demonstrated significant growth, with Carlyle Alpha Invest FRE increasing more than 80% year-to-date and Global Credit AUM reaching $208 billion, comprising 45% of firm-wide assets. Global Wealth recorded its best fundraising quarter ever with $3 billion in inflows.
- Carlyle issued $800 million of 10-year notes at 5% and repurchased over $200 million of stock in Q3 2025, reflecting a disciplined capital allocation strategy.
Oct 31, 2025, 12:30 PM
Carlyle Group Inc. Reports Q3 2025 Financial Results
CG
Earnings
Dividends
Share Buyback
- The Carlyle Group Inc. reported U.S. GAAP net income attributable to common stockholders of $0.9 million for Q3 2025, resulting in $0.00 basic and diluted earnings per share.
- On a non-GAAP basis, Distributable Earnings were $368 million pre-tax, or $0.96 per common share post-tax, and Fee Related Earnings were $312 million for Q3 2025.
- Total Assets Under Management grew 6% year-over-year to $474 billion, and Fee-earning Assets Under Management also increased 6% year-over-year to $332 billion as of September 30, 2025.
- The company declared a quarterly dividend of $0.35 per common share and repurchased 3.3 million shares totaling $0.2 billion during the quarter.
Oct 31, 2025, 12:30 PM
Carlyle Group Inc. Reports Q3 2025 Financial Results
CG
Earnings
Dividends
Guidance Update
- Carlyle Group Inc. reported income before provision for income taxes of $86 million and a margin of 25.8% on income before provision for income taxes for the third quarter ended September 30, 2025.
- The company generated $17 billion of organic quarterly inflows and had $474 billion of assets under management as of September 30, 2025.
- The Board of Directors declared a quarterly dividend of $0.35 per common share, payable on November 19, 2025, to holders of record on November 10, 2025.
- CEO Harvey M. Schwartz indicated that the company is well-positioned to exceed its updated 2025 financial targets.
Oct 30, 2025, 9:39 PM
Baxter Reports Third-Quarter 2025 Results
CG
Earnings
CEO Change
Product Launch
- Baxter reported third-quarter 2025 sales from continuing operations of $2.84 billion, an increase of 5% on a reported basis and 2% on an operational basis.
- Adjusted diluted earnings per share from continuing operations for the third quarter of 2025 was $0.69, marking a 41% increase over the prior year.
- Andrew Hider joined the company as president and chief executive officer (CEO).
- For full-year 2025, Baxter now expects sales growth from continuing operations of 4% to 5% on a reported basis and adjusted earnings from continuing operations of $2.35 to $2.40 per diluted share.
- The company launched the Welch Allyn Connex 360 Vital Signs Monitor, its next-generation patient monitoring device.
Oct 30, 2025, 11:15 AM
Carlyle Group's Fortitude Re Enters Funding Agreement Backed Note Market
CG
Debt Issuance
New Projects/Investments
- Fortitude Re, supported by investors including Carlyle, is entering the funding agreement backed note market with an inaugural offering.
- The offering consists of $500 million aggregate principal amount of 4.625% notes due Oct. 6, 2028, with settlement expected on October 6, 2025.
- These notes are anticipated to carry ratings of BBB+ from Fitch and A3 from Moody's.
- This strategic move is part of Fortitude Re's growth strategy to diversify capital sources and reinforce its balance sheet.
Sep 30, 2025, 2:35 PM
Quarterly earnings call transcripts for Carlyle Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more